PGx in psychiatry: Patients’ knowledge, interest, and uncertainty management preferences in the context of pharmacogenomic testing

Kastrinos, Amanda; Campbell‐Salome, Gemme; Shelton, Summer; Peterson, Emily; Bylund, Carma L.

doi:10.1016/j.pec.2020.12.021

Cited by 16 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Of the included studies, seven were conducted in the United States ( Shishko et al, 2015 ; Thompson et al, 2015 ; Goodspeed et al, 2019 ; Liko et al, 2020 ; McCarthy et al, 2020 ; Vest et al, 2020 ; Kastrinos et al, 2021 ), with the remaining studies being conducted in Canada ( Walden et al, 2015 ), France ( Laplace et al, 2021 ), Singapore ( Chan et al, 2017 ), and New Zealand ( Dunbar et al, 2012 ). Three of the studies gathered patient perspectives about PGx ( Liko et al, 2020 ; McCarthy et al, 2020 ; Kastrinos et al, 2021 ), while the remaining studies gathered HCPs viewpoints on PGx ( Dunbar et al, 2012 ; Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Chan et al, 2017 ; Goodspeed et al, 2019 ; McCarthy et al, 2020 ; Vest et al, 2020 ; Laplace et al, 2021 ). Data collection methods varied with some studies opting for focus groups ( Goodspeed et al, 2019 ; Vest et al, 2020 ), while one conducted semi-structured interviews ( Liko et al, 2020 ) and other studies collected data using a survey ( Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Kastrinos et al, 2021 ) or questionnaire ( Dunbar et al, 2012 ; Chan et al, 2017 ; McCarthy et al, 2020 ; Laplace et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…Three of the studies gathered patient perspectives about PGx ( Liko et al, 2020 ; McCarthy et al, 2020 ; Kastrinos et al, 2021 ), while the remaining studies gathered HCPs viewpoints on PGx ( Dunbar et al, 2012 ; Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Chan et al, 2017 ; Goodspeed et al, 2019 ; McCarthy et al, 2020 ; Vest et al, 2020 ; Laplace et al, 2021 ). Data collection methods varied with some studies opting for focus groups ( Goodspeed et al, 2019 ; Vest et al, 2020 ), while one conducted semi-structured interviews ( Liko et al, 2020 ) and other studies collected data using a survey ( Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Kastrinos et al, 2021 ) or questionnaire ( Dunbar et al, 2012 ; Chan et al, 2017 ; McCarthy et al, 2020 ; Laplace et al, 2021 ). The study setting varied also, with the majority of studies being conducted in secondary care settings ( Dunbar et al, 2012 ; Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Chan et al, 2017 ; Goodspeed et al, 2019 ; Liko et al, 2020 ; McCarthy et al, 2020 ), while one was carried out in both primary and secondary care settings ( Vest et al, 2020 ), and two studies were unspecified ( Kastrinos et al, 2021 ; Laplace et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

“…Data collection methods varied with some studies opting for focus groups ( Goodspeed et al, 2019 ; Vest et al, 2020 ), while one conducted semi-structured interviews ( Liko et al, 2020 ) and other studies collected data using a survey ( Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Kastrinos et al, 2021 ) or questionnaire ( Dunbar et al, 2012 ; Chan et al, 2017 ; McCarthy et al, 2020 ; Laplace et al, 2021 ). The study setting varied also, with the majority of studies being conducted in secondary care settings ( Dunbar et al, 2012 ; Shishko et al, 2015 ; Thompson et al, 2015 ; Walden et al, 2015 ; Chan et al, 2017 ; Goodspeed et al, 2019 ; Liko et al, 2020 ; McCarthy et al, 2020 ), while one was carried out in both primary and secondary care settings ( Vest et al, 2020 ), and two studies were unspecified ( Kastrinos et al, 2021 ; Laplace et al, 2021 ). A summary of the sample, data collection methods, barriers and enablers for each study can be found in Supplementary Appendix 2 .…”

Section: Resultsmentioning

confidence: 99%

“…Patients surveyed in two studies by McCarthy et al (2020) ; Kastrinos et al (2021) had positive outlooks overall on the use of PGx in psychiatry. Kastrinos et al (2021) demonstrated a high level of interest among patients and positive attitudes toward the use of PGx, while McCarthy et al (2020) found patients strongly agreed with PGx testing, if it can help them find appropriate treatment and allow patients to plan for the future more effectively.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?

et al. 2021

View full text Add to dashboard Cite

In psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). These both contribute to poor levels of adherence. Pharmacogenetics (PGx) considers how genetic variation can influence an individual’s response to a drug. Pharmacogenetic testing is a tool that could aid clinicians when selecting psychotropic medications, as part of a more personalized approach to prescribing. This may improve the use of and adherence to these medications. Yet to date, the implementation of PGx in mental health environments in the United Kingdom has been slow. This review aims to identify the current barriers and enablers to the implementation of PGx in psychiatry and determine how this can be applied to the uptake of PGx by NHS mental health providers. A systematic searching strategy was developed, and searches were carried out on the PsychInfo, EmBase, and PubMed databases, yielding 11 appropriate papers. Common barriers to the implementation of PGx included cost, concerns over incorporation into current workflow and a lack of knowledge about PGx; whilst frequent enablers included optimism that PGx could lead to precision medicine, reduce ADRs and become a more routine part of psychiatric clinical care. The uptake of PGx in psychiatric care settings in the NHS should consider and overcome these barriers, while looking to capitalize on the enablers identified in this review.

show abstract